Introduction and Epidemiology

Disease Overview

  • Non-Hodgkin Lymphoma (NHL) is a heterogeneous group of high-grade lymphoproliferative neoplasms arising from malignant B or T lymphoid progenitor cells.
  • Lymphomas represent the third most common pediatric malignancy, accounting for 10-15% of all childhood cancers.
  • NHL constitutes approximately 60% of all childhood lymphomas, while Hodgkin Lymphoma accounts for the remaining 40%.
  • Pediatric NHL accounts for 6-8% of total childhood cancers in patients under 20 years of age.

Epidemiological Characteristics

  • The annual incidence of pediatric NHL is approximately 7-10 cases per million children or 1 per 100,000.
  • In India, the reported incidence of NHL among pediatric malignancies ranges from 12% to 25%.
  • There is a marked male preponderance, with a male-to-female ratio of 3:1 in children under 15 years.
  • NHL is uncommon in children younger than 3 years of age.
  • The incidence increases steadily with age, peaking during the second decade of life.
  • Unlike adult NHL, which is predominantly indolent and nodal, pediatric NHL is overwhelmingly high-grade (>95%), rapidly proliferating, and extranodal (>70% presenting with advanced Stage III or IV disease).

Histopathological Classification and Biology

Comparative Subtype Characteristics

SubtypeImmunophenotypeHistopathology & CytogeneticsCommon Clinical Sites
Burkitt Lymphoma (BL)Mature B-cell (sIg+, PAX5, CD10, CD19, CD20, CD22, CD38, CD79a, kappa/lambda+)Starry-sky pattern; Ki-67 >99%; t(8;14)(q24;q32), t(2;8), t(8;22) MYC translocationsAbdomen (ileocecal), head/neck (Waldeyer ring, jaw), testes, bone marrow
Lymphoblastic Lymphoma (LL)Immature T-cell (70%) or precursor B-cell (30%); TdT+, CD34+Convoluted lymphoblasts; T-cell receptor rearrangements t(1;14), t(11;14), del 9pAnterior mediastinum, bone marrow, skin, bone, central nervous system
Diffuse Large B-Cell Lymphoma (DLBCL)Mature B-cell (CD19, CD20, CD22, CD38, CD79a)Diffuse growth of large cells; 2p16 amplification, 1p36 deletion, t(8;14) in 30%Nodal, abdominal, mediastinal (PMBL variant)
Anaplastic Large Cell Lymphoma (ALCL)Mature T-cell / null cell; CD30+, ALK (CD246)+, EMA+Pleomorphic cells with horseshoe nuclei; t(2;5)(p23;q35) NPM-ALK fusionLymph nodes, skin, bone, visceral organs, soft tissue

Detailed Subtype Profiles

Burkitt Lymphoma

  • Burkitt Lymphoma represents 19-38% of all pediatric NHL cases.
  • Histopathology shows a diffuse monomorphic infiltrate of medium-sized lymphoid cells with round nuclei and basophilic vacuolated cytoplasm.
  • Benign macrophages phagocytosing apoptotic debris create the classic starry-sky appearance.
  • Driven by MYC oncogene dysregulation resulting from chromosomal translocations involving immunoglobulin locus promoters.
  • Secondary mutations frequently involve TCF3, ID3, ARID1A, and SMARCA4 genes.

Lymphoblastic Lymphoma

  • Lymphoblastic Lymphoma accounts for approximately 20-29% of pediatric NHL cases.
  • Biologically and morphologically identical to acute lymphoblastic leukemia (ALL).
  • T-cell LL accounts for 70-80% of LL cases and typically presents as a rapidly expanding anterior mediastinal mass.
  • B-cell precursor LL accounts for 20-30% of cases and presents as localized lymphadenopathy, cutaneous nodules, or isolated bone lesions.

Diffuse Large B-Cell Lymphoma

  • Accounts for 10-20% of pediatric NHL cases.
  • The majority belong to the favorable germinal center B-cell-like subtype.
  • Primary Mediastinal Large B-Cell Lymphoma (PMBL) is a distinct subtype sharing molecular features with Hodgkin Lymphoma and carrying a less favorable prognosis with standard regimens.

Anaplastic Large Cell Lymphoma

  • Represents approximately 10-17% of pediatric NHL cases.
  • Characterized by large pleomorphic lymphoid cells with abundant cytoplasm and eccentric horseshoe-shaped or kidney-shaped nuclei.
  • Over 90% of pediatric ALCL cases express anaplastic lymphoma kinase (ALK) fusion protein due to the t(2;5)(p23;q35) translocation.

Rare Pediatric Lymphomas

  • Includes Pediatric-type Follicular Lymphoma (PFL), which carries 1p36 deletion and MAP2K1 mutations without BCL2 rearrangements.
  • Other rare entities include Pediatric Marginal Zone Lymphoma and MALT Lymphoma.

Distinguishing Features: Non-Hodgkin vs Hodgkin Lymphoma

Clinical / Biological FeatureHodgkin LymphomaNon-Hodgkin Lymphoma
Anatomical ExtentLocalized to nodal groupsDisseminated, extranodal presentation common
Pattern of SpreadContiguous orderly spread to adjacent nodesDiscontinuous non-contiguous spread
Extranodal DiseaseRareCommon (>70% of cases at diagnosis)
Abdominal InvolvementUncommonCommon (especially Burkitt subtype)
Bone Marrow & CNS InvolvementRare (<5-10%)Common (up to 20-30% at diagnosis)
Systemic B SymptomsPresent in 20-30%; prognosticPresent in 8-10% (higher in ALCL); non-prognostic
Growth FractionLow to variable growth fractionExtremely high growth fraction
Treatment BasisRisk-stratified by stage and B symptomsSubtype-specific intensive multiagent chemotherapy
Overall Survival Rates85-90%70-90%

Clinical Presentation and Emergencies

Organ-Specific Presentations

  • Abdominal Presentations: Most frequent in Burkitt Lymphoma. Patients present with abdominal pain, ascites, a rapidly expanding right lower quadrant mass, or acute ileocecal intussusception.
  • Intrathoracic Presentations: Most frequent in T-cell Lymphoblastic Lymphoma. Patients present with cough, dyspnea, orthopnea, stridor, and pleural or pericardial effusions.
  • Head and Neck Presentations: Cervical lymphadenopathy, tonsillar hypertrophy (Waldeyer ring involvement), or jaw swelling.

Oncologic Emergencies

  • Superior Mediastinal Syndrome / SVC Obstruction: Caused by compression of the trachea and superior vena cava by an anterior mediastinal mass. Requires urgent administration of intravenous dexamethasone.
  • Acute Tumor Lysis Syndrome (TLS): High risk in Burkitt and Lymphoblastic Lymphoma due to rapid tumor growth. Causes hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acute oliguric renal failure.
  • Spinal Cord Compression: Caused by paraspinal or epidural tumor extension leading to paraplegia, sensory deficits, or bowel/bladder dysfunction. Requires emergency high-dose corticosteroids and prompt cytoreductive therapy.

Staging and Risk Stratification

Murphy / St. Jude Staging System

  • Stage I: A single extranodal tumor or single anatomical nodal area, excluding the mediastinum or abdomen.
  • Stage II: A single extranodal tumor with regional node involvement; OR two or more nodal areas on the same side of the diaphragm; OR a completely resected primary gastrointestinal tract tumor ± mesenteric nodes.
  • Stage III: Two single extranodal tumors on opposite sides of the diaphragm; OR two or more nodal areas above and below the diaphragm; OR any primary intrathoracic tumor; OR extensive intra-abdominal disease; OR any paraspinal/epidural tumor.
  • Stage IV: Any of the above stages with initial central nervous system (CNS) and/or bone marrow (BM) involvement (defined as ≤25% blasts in marrow).

International Pediatric Non-Hodgkin Lymphoma Staging System

  • International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) incorporates modern flow cytometry, molecular assays, and PET-CT imaging.
  • Stage IV BM is defined morphologically by ≥5% blasts in bone marrow aspiration.
  • Sub-classifies marrow involvement as BMm (morphology positive), BMi (immunophenotypic positive), or BMmol (molecular positive).

Diagnostic Evaluation

Histopathological and Molecular Workup

  • Excisional or core lymph node biopsy is the gold standard for diagnosis.
  • Diagnostic panel must include histopathology, immunohistochemistry, immunophenotyping by flow cytometry, cytogenetics/FISH, and molecular diagnostics.
  • In patients with severe respiratory compromise from a mediastinal mass, diagnosis can be established using percutaneous needle aspiration, fluid cytology (pleural/peritoneal), or bone marrow aspiration.

Staging Investigations

  • Laboratory Panel: Complete blood count, peripheral smear, liver function tests, renal function tests, serum electrolytes, uric acid, and lactate dehydrogenase (LDH).
  • Bone Marrow Examination: Bilateral iliac crest bone marrow aspirates and trephine core biopsies.
  • Central Nervous System Evaluation: Lumbar puncture with CSF cytomorphology and flow cytometry.
  • Diagnostic Imaging: Contrast-enhanced CT or MRI of neck, chest, abdomen, and pelvis. Positron emission tomography (FDG-PET/CT) for baseline staging and response assessment. Echocardiogram prior to anthracycline therapy.

Management Principles

Supportive Care and Tumor Lysis Syndrome

  • Vigorous intravenous hydration at 2-3 L/m²/day without added potassium.
  • Rasburicase (recombinant urate oxidase) administered at 0.2 mg/kg/day IV for rapid clearance of uric acid.
  • Rasburicase is strictly contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of severe hemolysis.
  • Allopurinol (10 mg/kg/day orally in 3 divided doses) is utilized in low-risk cases or when rasburicase is contraindicated.

Subtype-Specific Chemotherapy Protocols

Mature B-Cell Lymphomas

  • Burkitt Lymphoma and DLBCL are treated with short-duration (3-6 months), pulse-intensive multiagent chemoimmunotherapy.
  • Low-stage disease: 2-4 cycles of COPAD (cyclophosphamide, vincristine, prednisone, doxorubicin) or CHOP.
  • Advanced-stage disease: FAB-LMB 96 protocol (fractionated cyclophosphamide, high-dose methotrexate, vincristine, doxorubicin, cytarabine, etoposide) combined with anti-CD20 monoclonal antibody (Rituximab).

Lymphoblastic Lymphoma

  • Treated on long-duration (2 years) leukemia-like protocols with continuous cytostatic exposure.
  • Regimens include BFM-95 or COG A5971, comprising induction, consolidation, CNS prophylaxis, and long-term maintenance phases.

Anaplastic Large Cell Lymphoma

  • Regimens include CHOP, APO (doxorubicin, prednisone, vincristine), BFM-NHL90, or ALCL 99.
  • Targetable agents include Crizotinib (oral ALK tyrosine kinase inhibitor) and Brentuximab Vedotin (anti-CD30 antibody-drug conjugate).

Role of Immunotherapy and Targeted Agents

  • Rituximab (anti-CD20 antibody) significantly improves event-free survival in mature B-cell NHL.
  • Crizotinib targets NPM-ALK fusion tyrosine kinase in ALCL.
  • Brentuximab Vedotin delivers cytotoxic payload to CD30-expressing ALCL cells.
  • Dose-adjusted EPOCH-R is utilized for Primary Mediastinal Large B-Cell Lymphoma.

Role of Surgery and Radiotherapy

  • Surgery: Role is limited to diagnostic biopsy and complete resection of primary localized gastrointestinal tumors (ileocecal).
  • Radiotherapy: Reserved for acute oncologic emergencies (tracheal compression, spinal cord compression) or specific CNS disease presentations.

Prognosis, Relapse, and Late Effects

Survival Outcomes

  • Event-free survival (EFS) exceeds 90-95% for localized low-stage NHL.
  • EFS ranges from 80% to 90% for advanced-stage (Stage III/IV) disease with modern chemoimmunotherapy.

Relapse Management

  • Relapsed NHL carries a poor prognosis, particularly in Burkitt and Lymphoblastic Lymphoma.
  • Reinduction chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplantation (HSCT) is utilized.
  • Novel targeted agents under investigation include Obinutuzumab, Ibrutinib, and Idelalisib.

Late Effects of Therapy

  • Anthracycline-induced cardiotoxicity.
  • Secondary leukemias (AML/MDS) from alkylating agents and topoisomerase II inhibitors.
  • Gonadal toxicity resulting in infertility.
  • Neurocognitive deficits secondary to intrathecal chemotherapy or cranial radiation.
  • Growth retardation and endocrine dysfunction.